Journal of Chest Surgery

The Korean Society for Thoracic and Cardiovascular Surgery (대한심장혈관흉부외과학회)
권호 표지
DOI QR코드

DOI QR Code

Expression of the Brother of the Regulator of Imprinted Sites Gene in the Sputum of Patients with Lung Cancer

  • Lee, Hae Young (Department of Thoracic and Cardiovascular Surgery, Kosin University Gospel Hospital, Kosin University College of Medicine) ;
  • Kim, Jong In (Department of Thoracic and Cardiovascular Surgery, Kosin University Gospel Hospital, Kosin University College of Medicine) ;
  • Cho, Sung Ho (Department of Thoracic and Cardiovascular Surgery, Kosin University Gospel Hospital, Kosin University College of Medicine) ;
  • Ko, Taek Yong (Department of Thoracic and Cardiovascular Surgery, Kosin University Gospel Hospital, Kosin University College of Medicine) ;
  • Kim, Hyun Su (Department of Thoracic and Cardiovascular Surgery, Kosin University Gospel Hospital, Kosin University College of Medicine) ;
  • Park, Sung Dal (Department of Thoracic and Cardiovascular Surgery, Kosin University Gospel Hospital, Kosin University College of Medicine) ;
  • Cho, Sung Rae (Department of Thoracic and Cardiovascular Surgery, Kosin University Gospel Hospital, Kosin University College of Medicine) ;
  • Chang, Hee Kyung (Department of Pathology, Kosin University Gospel Hospital, Kosin University College of Medicine) ;
  • Hwang, Guk Jin (Department of Familly Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine) ;
  • Jung, Sang Bong (Department of Clinical Laboratory Science, Gimhae College)
  • Received : 2013.10.11
  • Accepted : 2013.11.24
  • Published : 2014.08.05
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Brother of the regulator of imprinted sites (BORIS) is a putative new oncogene that is classified as a cancer germline gene; however, its role in the development of cancer is unclear. This study investigated the expression of BORIS in lung cancer and its clinical implications. Methods: The expression of BORIS messenger ribonucleic acid (mRNA) in the sputum of 100 patients with lung cancer (50 with squamous cell carcinoma, 36 with adenocarcinoma, and 14 with small-cell carcinoma) was evaluated by reverse transcription polymerase chain reaction. Results: The overall expression rate of BORIS in patients with lung cancer was 36.0%: 19 of 50 squamous cell carcinomas (38.0%), 13 of 36 adenocarcinomas (36.1%), and 4 of 14 (28.6%) small-cell carcinomas. There was no significant difference in the BORIS expression according to age, gender, or histologic type. However, the mRNA expression of BORIS was significantly related to the pathologic cancer stage (p=0.004) and lymph node metastasis (p=0.001). The expression of the melanoma antigen gene family A1-6 was not associated with the expression of BORIS. Conclusion: Our results suggest that the expression of BORIS might be a negative prognostic factor in lung cancers and implicate BORIS as a molecular target for immunotherapy.

Keywords

References

  1. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005;5:615-25. https://doi.org/10.1038/nrc1669
  2. Woloszynska-Read A, James SR, Link PA, Yu J, Odunsi K, Karpf AR. DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer Immun 2007;7:21.
  3. Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res 2001;61:5544-51.
  4. De Plaen E, Arden K, Traversari C, et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 1994;40:360-9. https://doi.org/10.1007/BF01246677
  5. Park JW, Kwon TK, Kim IH, et al. A new strategy for the diagnosis of MAGE-expressing cancers. J Immunol Methods 2002;266:79-86. https://doi.org/10.1016/S0022-1759(02)00105-9
  6. Melenhorst JJ, Barrett AJ. Tumor vaccines and beyond. Cytotherapy 2011;13:8-18. https://doi.org/10.3109/14653249.2010.530649
  7. Mellstedt H, Vansteenkiste J, Thatcher N. Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience. Lung Cancer 2011;73:11-7. https://doi.org/10.1016/j.lungcan.2011.02.023
  8. De Necochea-Campion R, Ghochikyan A, Josephs SF, et al. Expression of the epigenetic factor BORIS (CTCFL) in the human genome. J Transl Med 2011;9:213. https://doi.org/10.1186/1479-5876-9-213
  9. D'Arcy V, Pore N, Docquier F, et al. BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours. Br J Cancer 2008;98:571-9. https://doi.org/10.1038/sj.bjc.6604181
  10. Risinger JI, Chandramouli GV, Maxwell GL, et al. Global expression analysis of cancer/testis genes in uterine cancers reveals a high incidence of BORIS expression. Clin Cancer Res 2007;13:1713-9. https://doi.org/10.1158/1078-0432.CCR-05-2569
  11. Kholmanskikh O, Loriot A, Brasseur F, De Plaen E, De Smet C. Expression of BORIS in melanoma: lack of association with MAGE-A1 activation. Int J Cancer 2008;122:777-84. https://doi.org/10.1002/ijc.23140
  12. Woloszynska-Read A, Zhang W, Yu J, et al. Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage. Clin Cancer Res 2011;17:2170-80. https://doi.org/10.1158/1078-0432.CCR-10-2315
  13. Smith IM, Glazer CA, Mithani SK, et al. Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. PLoS One 2009;4:e4961. https://doi.org/10.1371/journal.pone.0004961
  14. Fiorentino FP, Macaluso M, Miranda F, et al. CTCF and BORIS regulate Rb2/p130 gene transcription: a novel mechanism and a new paradigm for understanding the biology of lung cancer. Mol Cancer Res 2011;9:225-33. https://doi.org/10.1158/1541-7786.MCR-10-0493
  15. Bhan S, Negi SS, Shao C, et al. BORIS binding to the promoters of cancer testis antigens, MAGEA2, MAGEA3, and MAGEA4, is associated with their transcriptional activation in lung cancer. Clin Cancer Res 2011;17:4267-76. https://doi.org/10.1158/1078-0432.CCR-11-0653
  16. Okabayashi K, Fujita T, Miyazaki J, et al. Cancer-testis antigen BORIS is a novel prognostic marker for patients with esophageal cancer. Cancer Sci 2012;103:1617-24. https://doi.org/10.1111/j.1349-7006.2012.02355.x
  17. Loukinov D, Ghochikyan A, Mkrtichyan M, et al. Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant. J Cell Biochem 2006;98:1037-43. https://doi.org/10.1002/jcb.20953

Cited by

  1. Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential vol.8, pp.1, 2014, https://doi.org/10.1177/1758834015615514